lncRNA PVT1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis
Authors Chen X, Yang Y, Cao Y, Wu C, Wu S, Su Z, Jin H, Wang D, Zhang G, Fan W, Lin J, Zeng Y, Hu D
Received 22 February 2018
Accepted for publication 7 May 2018
Published 16 August 2018 Volume 2018:10 Pages 2711—2727
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 3
Editor who approved publication: Dr Kenan Onel
Xiaoliang Chen,1,* Yueying Yang,2,* Yong Cao,1,* Changjun Wu,3 Shuxian Wu,3 Zhan Su,1 Hongwei Jin,1 Dongli Wang,1 Gengxin Zhang,3 Wei Fan,4 Jinbo Lin,5 Yunhong Zeng,3 Dongsheng Hu6
1The Center for Chronic Disease Control and Prevention, Shenzhen Guangming District Center for Disease Control and Prevention, Shenzhen, China; 2Science and Education Department, Shenzhen School of the Affiliated High School of Renmin University of China, Shenzhen, China; 3Department of Oncology, Guangming District People’s Hospital of Shenzhen, Shenzhen, China; 4Division of Digestive and Liver Disease, Cedars-Sinai Medical Center, Los Angeles, CA, USA; 5Department of Oncology, Longgang Central Hospital of Shenzhen Affiliated to Zunyi Medical College, Shenzhen, China; 6School of Medicine, Shenzhen University, Shenzhen, China
*These authors contributed equally to this work
Purpose: Long noncoding RNA PVT1 is dysregulated in some human tumors and has been found to increase the risk of tumor progression and poor prognosis. This study aimed to reanalyze the effect of PVT1 on tumorous prognosis.
Materials and methods: The effect of PVT1 on metastasis and survival were analyzed by univariate logistic regression and Cox proportional hazards model for 32 types of cancer in the Cancer Genome Atlas database (TCGA), and the relationship between PVT1 level and expression of relative genes was assessed by Pearson correlation analysis. RevMan5.3 and STATA14.0 were used to estimate pooled effects of PVT1 on cancer prognosis with data from TCGA and published studies.
Results: In TCGA data, high PVT1 expression tended to increase the risk of TNM progression and decreased the overall survival (OS) time in most of cancers. The pooled effect of PVT1 on TNM (pooled-OR=1.46, 95% CI: 1.29–1.65) and OS (pooled HR=1.32, 95% CI: 1.22–1.43), calculated from 37 and 48 cohorts, identified that high PVT1 expression promoted the metastasis and poor prognosis of cancer. Furthermore, the pooled ORs of 2.77 (95% CI: 1.65–4.66), 4.32 (95% CI: 1.99–9.36), 1.35 (95% CI: 1.01–1.80), 1.62 (95% CI: 1.21–2.18) and 1.48 (95% CI: 1.02–2.15) provided evidence that PVT1 played a role in lymph node metastasis, depth of invasion, distant metastasis, differentiation and lymphatic invasion; while the expression of 24 identified target genes was significantly associated with PVT1 level, and high PVT1 expression dependently decreased the OS time under the influence of co-expression genes (OR=1.29, 95% CI: 1.25–1.32) in high-throughput RNA sequencing merging data. In addition, the expression of PVT1 could be upregulated by smoking, with the pooled OR being 1.09 (95% CI 1.01–1.16).
Conclusion: PVT1 is a dependent biomarker for tumorous prognosis surveillance. However, the reference value of PVT1 needs further study.
Keywords: PVT1, Cancer, biomarker, survive, metastasis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]